Drugs · Brain health technique
GM-CSF (Sargramostim / Leukine®)
Evidence grade: Experimental
A recombinant human granulocyte–macrophage colony-stimulating factor (GM-CSF) that stimulates innate immune activity and neuroinflammatory repair mechanisms; marketed as Leukine®, used in oncology and being tested for Alzheimer’s.
- Practice
- Drugs
- Principle
- Treatment
- Tactic
- Neuroprotective & Disease-modifying Therapies
- Evidence grade
- Experimental
- Strength of evidence
- Low
How to practice GM-CSF (Sargramostim / Leukine®)
Currently investigational for neurodegenerative use. Administered as subcutaneous injections (typically 250 µg/m² daily for 5 days/week over 3 weeks in trials). Available clinically only for hematologic and transplant indications. Off-label use not recommended outside clinical research due to uncertain safety and optimal dosing for brain health.
The evidence behind GM-CSF (Sargramostim / Leukine®)
Early RCTs from the University of Colorado (2021–2023) show that sargramostim improved cognition and reduced amyloid/tau pathology in mild-to-moderate Alzheimer’s. Mechanism: reactivation of microglia and recruitment of protective immune responses that clear debris and promote neuronal repair. Data remain preliminary with small sample sizes and short duration.
More Drugs techniques
Take control of your brain health
BetterBrain gives you a personalized protocol of techniques like these, backed by science and tailored to you.